BIOMARKER:

EGFR mutation

A1 | Sensitive

A2 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

A2 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Lung Adenocarcinoma

Lung Non-Squamous Non-Small Cell Cancer

Lung Cancer

Glioblastoma

Lung Non-Small Cell Squamous Cancer

Solid Tumor

Esophageal Squamous Cell Carcinoma

Gastric Cancer

Squamous Cell Carcinoma of Head and Neck

Small Cell Lung Cancer

Triple Negative Breast Cancer

Thyroid Gland Carcinoma

Mesothelioma

Colorectal Cancer

Ovarian Cancer

Breast Cancer

Melanoma

Immunotherapy + Angiogenesis inhibitor

EGFR mutation|Non Small Cell Lung Cancer|Immunotherapy + Angiogenesis inhibitor

EGFR inhibitor

EGFR mutation|Non Small Cell Lung Cancer|EGFR inhibitor

EGFR mutation|Lung Adenocarcinoma|EGFR inhibitor

EGFR mutation|Lung Cancer|EGFR inhibitor

EGFR mutation|Small Cell Lung Cancer|EGFR inhibitor

EGFR mutation|Colorectal Cancer|EGFR inhibitor

PD-L1 inhibitor + CD73 inhibitor

EGFR mutation|Non Small Cell Lung Cancer|PD-L1 inhibitor + CD73 inhibitor

Immunotherapy

EGFR mutation|Non Small Cell Lung Cancer|Immunotherapy

EGFR mutation|Lung Adenocarcinoma|Immunotherapy

EGFR mutation|Melanoma|Immunotherapy

ALK inhibitor

EGFR mutation|Non Small Cell Lung Cancer|ALK inhibitor

EGFR inhibitor + Tyrosine kinase inhibitor

EGFR mutation|Non Small Cell Lung Cancer|EGFR inhibitor + Tyrosine kinase inhibitor

EGFR inhibitor + Angiogenesis inhibitor

EGFR mutation|Non Small Cell Lung Cancer|EGFR inhibitor + Angiogenesis inhibitor

Tyrosine kinase inhibitor

EGFR mutation|Non Small Cell Lung Cancer|Tyrosine kinase inhibitor

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|Tyrosine kinase inhibitor

EGFR mutation|Lung Adenocarcinoma|Tyrosine kinase inhibitor

EGFR mutation|Lung Non-Small Cell Squamous Cancer|Tyrosine kinase inhibitor

PD1 inhibitor + Angiogenesis inhibitor

EGFR mutation|Non Small Cell Lung Cancer|PD1 inhibitor + Angiogenesis inhibitor

PD-L1 inhibitor

EGFR mutation|Non Small Cell Lung Cancer|PD-L1 inhibitor

ABCP

EGFR mutation|Non Small Cell Lung Cancer|ABCP

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|ABCP

GCP

EGFR mutation|Non Small Cell Lung Cancer|GCP

erlotinib + ramucirumab

EGFR mutation|Non Small Cell Lung Cancer|erlotinib + ramucirumab

bevacizumab

EGFR mutation|Non Small Cell Lung Cancer|bevacizumab

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|bevacizumab

EGFR mutation|Lung Adenocarcinoma|bevacizumab

EGFR mutation|Lung Non-Small Cell Squamous Cancer|bevacizumab

EGFR mutation|Ovarian Cancer|bevacizumab

erlotinib

EGFR mutation|Non Small Cell Lung Cancer|erlotinib

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|erlotinib

EGFR mutation|Lung Adenocarcinoma|erlotinib

EGFR mutation|Lung Cancer|erlotinib

EGFR mutation|Glioblastoma|erlotinib

afatinib

EGFR mutation|Non Small Cell Lung Cancer|afatinib

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|afatinib

EGFR mutation|Lung Adenocarcinoma|afatinib

EGFR mutation|Esophageal Squamous Cell Carcinoma|afatinib

EGFR mutation|Gastric Cancer|afatinib

osimertinib

EGFR mutation|Non Small Cell Lung Cancer|osimertinib

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|osimertinib

EGFR mutation|Lung Adenocarcinoma|osimertinib

EGFR mutation|Lung Cancer|osimertinib

gefitinib

EGFR mutation|Non Small Cell Lung Cancer|gefitinib

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|gefitinib

EGFR mutation|Lung Adenocarcinoma|gefitinib

EGFR mutation|Lung Cancer|gefitinib

bevacizumab + afatinib

EGFR mutation|Non Small Cell Lung Cancer|bevacizumab + afatinib

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|bevacizumab + afatinib

EGFR mutation|Lung Adenocarcinoma|bevacizumab + afatinib

bevacizumab + erlotinib

EGFR mutation|Non Small Cell Lung Cancer|bevacizumab + erlotinib

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|bevacizumab + erlotinib

EGFR mutation|Lung Adenocarcinoma|bevacizumab + erlotinib

icotinib

EGFR mutation|Non Small Cell Lung Cancer|icotinib

EGFR mutation|Lung Adenocarcinoma|icotinib

EGFR mutation|Lung Cancer|icotinib

U3-1402

EGFR mutation|Non Small Cell Lung Cancer|U3-1402

gefitinib + rivoceranib

EGFR mutation|Non Small Cell Lung Cancer|gefitinib + rivoceranib

AK112

EGFR mutation|Non Small Cell Lung Cancer|AK112

AZD3759

EGFR mutation|Non Small Cell Lung Cancer|AZD3759

ERAS-801

EGFR mutation|Glioblastoma|ERAS-801

SIBP-04 (bevacizumab biosimilar)

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|SIBP-04 (bevacizumab biosimilar)

pemetrexed

EGFR mutation|Non Small Cell Lung Cancer|pemetrexed

EGFR mutation|Lung Adenocarcinoma|pemetrexed

aumolertinib

EGFR mutation|Non Small Cell Lung Cancer|aumolertinib

EGFR mutation|Lung Adenocarcinoma|aumolertinib

bevacizumab + atezolizumab

EGFR mutation|Non Small Cell Lung Cancer|bevacizumab + atezolizumab

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|bevacizumab + atezolizumab

erlotinib + ABBV-399

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|erlotinib + ABBV-399

EGFR mutation|Lung Non-Small Cell Squamous Cancer|erlotinib + ABBV-399

anlotinib

EGFR mutation|Non Small Cell Lung Cancer|anlotinib

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|anlotinib

EGFR mutation|Lung Adenocarcinoma|anlotinib

bevacizumab + osimertinib

EGFR mutation|Non Small Cell Lung Cancer|bevacizumab + osimertinib

EGFR mutation|Lung Cancer|bevacizumab + osimertinib

sintilimab

EGFR mutation|Non Small Cell Lung Cancer|sintilimab

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|sintilimab

tislelizumab

EGFR mutation|Non Small Cell Lung Cancer|tislelizumab

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|tislelizumab

toripalimab-tpzi

EGFR mutation|Non Small Cell Lung Cancer|toripalimab-tpzi

BPI-361175

EGFR mutation|Non Small Cell Lung Cancer|BPI-361175

MET306

EGFR mutation|Non Small Cell Lung Cancer|MET306

DZD9008

EGFR mutation|Non Small Cell Lung Cancer|DZD9008

bevacizumab + aumolertinib

EGFR mutation|Non Small Cell Lung Cancer|bevacizumab + aumolertinib

MCLA-129

EGFR mutation|Non Small Cell Lung Cancer|MCLA-129

osimertinib + abemaciclib

EGFR mutation|Lung Cancer|osimertinib + abemaciclib

BL-B01D1

EGFR mutation|Non Small Cell Lung Cancer|BL-B01D1

SNK01

EGFR mutation|Non Small Cell Lung Cancer|SNK01

BLU-945

EGFR mutation|Non Small Cell Lung Cancer|BLU-945

AFM24

EGFR mutation|Non Small Cell Lung Cancer|AFM24

aumolertinib + HS-10241

EGFR mutation|Non Small Cell Lung Cancer|aumolertinib + HS-10241

anlotinib + aumolertinib

EGFR mutation|Non Small Cell Lung Cancer|anlotinib + aumolertinib

amivantamab-vmjw

EGFR mutation|Non Small Cell Lung Cancer|amivantamab-vmjw

anlotinib + sintilimab

EGFR mutation|Non Small Cell Lung Cancer|anlotinib + sintilimab

DS-1062a

EGFR mutation|Non Small Cell Lung Cancer|DS-1062a

ORIC-114

EGFR mutation|Solid Tumor|ORIC-114

cetuximab + afatinib

EGFR mutation|Non Small Cell Lung Cancer|cetuximab + afatinib

EGFR mutation|Lung Adenocarcinoma|cetuximab + afatinib

ASP8273

EGFR mutation|Non Small Cell Lung Cancer|ASP8273

osimertinib + rivoceranib

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + rivoceranib

nivolumab

EGFR mutation|Non Small Cell Lung Cancer|nivolumab

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|nivolumab

cetuximab + ISU104

EGFR mutation|Squamous Cell Carcinoma of Head and Neck|cetuximab + ISU104

gefitinib + savolitinib

EGFR mutation|Non Small Cell Lung Cancer|gefitinib + savolitinib

ipilimumab

EGFR mutation|Non Small Cell Lung Cancer|ipilimumab

furmonertinib

EGFR mutation|Non Small Cell Lung Cancer|furmonertinib

ABSK091

EGFR mutation|Solid Tumor|ABSK091

cisplatin + albumin-bound paclitaxel

EGFR mutation|Non Small Cell Lung Cancer|cisplatin + albumin-bound paclitaxel

erlotinib + anlotinib

EGFR mutation|Non Small Cell Lung Cancer|erlotinib + anlotinib

pembrolizumab + INCB024360

EGFR mutation|Lung Adenocarcinoma|pembrolizumab + INCB024360

gefitinib + anlotinib

EGFR mutation|Non Small Cell Lung Cancer|gefitinib + anlotinib

SHR-1701

EGFR mutation|Non Small Cell Lung Cancer|SHR-1701

rociletinib

EGFR mutation|Non Small Cell Lung Cancer|rociletinib

EGFR mutation|Non Small Cell Lung Cancer|

amivantamab-vmjw + lazertinib

EGFR mutation|Non Small Cell Lung Cancer|amivantamab-vmjw + lazertinib

carboplatin + docetaxel

EGFR mutation|Triple Negative Breast Cancer|carboplatin + docetaxel

BDTX-189

EGFR mutation|Solid Tumor|BDTX-189

osimertinib + dasatinib

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + dasatinib

nivolumab + ipilimumab

EGFR mutation|Non Small Cell Lung Cancer|nivolumab + ipilimumab

sintilimab + Byvasda (bevacizumab biosimilar)

EGFR mutation|Lung Non-Squamous Non-Small Cell Cancer|sintilimab + Byvasda (bevacizumab biosimilar)

osimertinib + APG-1252

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + APG-1252

osimertinib + CB-228

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + CB-228

BBT-176

EGFR mutation|Non Small Cell Lung Cancer|BBT-176

osimertinib + savolitinib

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + savolitinib

ramucirumab

EGFR mutation|Non Small Cell Lung Cancer|ramucirumab

zimberelimab + AB928

EGFR mutation|Non Small Cell Lung Cancer|zimberelimab + AB928

verteporfin

EGFR mutation|Glioblastoma|verteporfin

BMS-986466

EGFR mutation|Non Small Cell Lung Cancer|BMS-986466

anlotinib + icotinib

EGFR mutation|Non Small Cell Lung Cancer|anlotinib + icotinib

AUY922

EGFR mutation|Non Small Cell Lung Cancer|AUY922

osimertinib + selumetinib

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + selumetinib

osimertinib + ramucirumab

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + ramucirumab

EGF816

EGFR mutation|Non Small Cell Lung Cancer|EGF816

camrelizumab + rivoceranib

EGFR mutation|Non Small Cell Lung Cancer|camrelizumab + rivoceranib

durvalumab + MEDI9447

EGFR mutation|Non Small Cell Lung Cancer|durvalumab + MEDI9447

albumin-bound paclitaxel

EGFR mutation|Non Small Cell Lung Cancer|albumin-bound paclitaxel

nintedanib

EGFR mutation|Non Small Cell Lung Cancer|nintedanib

osimertinib + afatinib

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + afatinib

osimertinib + anlotinib

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + anlotinib

lazertinib

EGFR mutation|Non Small Cell Lung Cancer|lazertinib

HMPL-813

EGFR mutation|Non Small Cell Lung Cancer|HMPL-813

atezolizumab

EGFR mutation|Non Small Cell Lung Cancer|atezolizumab

irinotecan + gimeracil/oteracil/tegafur

EGFR mutation|Non Small Cell Lung Cancer|irinotecan + gimeracil/oteracil/tegafur

BPI-7711

EGFR mutation|Non Small Cell Lung Cancer|BPI-7711

bevacizumab + PSB205

EGFR mutation|Non Small Cell Lung Cancer|bevacizumab + PSB205

gefitinib + AB-329

EGFR mutation|Non Small Cell Lung Cancer|gefitinib + AB-329

osimertinib + MEDI9447

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + MEDI9447

osimertinib + AB-329

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + AB-329

BDTX-1535

EGFR mutation|Non Small Cell Lung Cancer|BDTX-1535

EGFR mutation|Glioblastoma|BDTX-1535

MEDI9447

EGFR mutation|Non Small Cell Lung Cancer|MEDI9447

afatinib + ramucirumab

EGFR mutation|Non Small Cell Lung Cancer|afatinib + ramucirumab

pembrolizumab

EGFR mutation|Non Small Cell Lung Cancer|pembrolizumab

cetuximab + SNK01

EGFR mutation|Non Small Cell Lung Cancer|cetuximab + SNK01

osimertinib + BLU-945

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + BLU-945

BNT327

EGFR mutation|Non Small Cell Lung Cancer|BNT327

trastuzumab + osimertinib + necitumumab

EGFR mutation|Non Small Cell Lung Cancer|trastuzumab + osimertinib + necitumumab

KN046

EGFR mutation|Non Small Cell Lung Cancer|KN046

GB263T

EGFR mutation|Non Small Cell Lung Cancer|GB263T

dacomitinib

EGFR mutation|Non Small Cell Lung Cancer|dacomitinib

erlotinib + binimetinib

EGFR mutation|Non Small Cell Lung Cancer|erlotinib + binimetinib

camrelizumab + SHR 1020

EGFR mutation|Non Small Cell Lung Cancer|camrelizumab + SHR 1020

poziotinib

EGFR mutation|Non Small Cell Lung Cancer|poziotinib

osimertinib + MCLA-129

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + MCLA-129

pembrolizumab + anlotinib

EGFR mutation|Lung Adenocarcinoma|pembrolizumab + anlotinib

durvalumab

EGFR mutation|Non Small Cell Lung Cancer|durvalumab

lurbinectedin

EGFR mutation|Lung Adenocarcinoma|lurbinectedin

olaparib + gefitinib

EGFR mutation|Non Small Cell Lung Cancer|olaparib + gefitinib

M1231

EGFR mutation|Non Small Cell Lung Cancer|M1231

osimertinib + U3-1402

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + U3-1402

atezolizumab + temozolomide

EGFR mutation|Glioblastoma|atezolizumab + temozolomide

VT-104

EGFR mutation|Lung Cancer|VT-104

afatinib + gefitinib

EGFR mutation|Lung Adenocarcinoma|afatinib + gefitinib

osimertinib + AU-15506

EGFR mutation|Lung Adenocarcinoma|osimertinib + AU-15506

SRF231

EGFR mutation|Non Small Cell Lung Cancer|SRF231

CKD-702

EGFR mutation|Non Small Cell Lung Cancer|CKD-702

EGFR mutation|Lung Adenocarcinoma|CKD-702

cisplatin + pemetrexed

EGFR mutation|Lung Adenocarcinoma|cisplatin + pemetrexed

osimertinib + BMS-986466

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + BMS-986466

vorolanib

EGFR mutation|Non Small Cell Lung Cancer|vorolanib

AEE788

EGFR mutation|Thyroid Gland Carcinoma|AEE788

afatinib + omtriptolide

EGFR mutation|Non Small Cell Lung Cancer|afatinib + omtriptolide

neratinib

EGFR mutation|Breast Cancer|neratinib

DRP-104

EGFR mutation|Lung Adenocarcinoma|DRP-104

OBI-998

EGFR mutation|Non Small Cell Lung Cancer|OBI-998

SHP099 + SX-682

EGFR mutation|Non Small Cell Lung Cancer|SHP099 + SX-682

GZ17-6.02

EGFR mutation|Non Small Cell Lung Cancer|GZ17-6.02

osimertinib + VT3989

EGFR mutation|Non Small Cell Lung Cancer|osimertinib + VT3989

IK-930

EGFR mutation|Non Small Cell Lung Cancer|IK-930

EGFR mutation|Mesothelioma|IK-930

EGFR mutation|Colorectal Cancer|IK-930

ERAS-601

EGFR mutation|Non Small Cell Lung Cancer|ERAS-601

ER121

EGFR mutation|Solid Tumor|ER121

AZD9592

EGFR mutation|Non Small Cell Lung Cancer|AZD9592

DB-1310

EGFR mutation|Non Small Cell Lung Cancer|DB-1310

osimertinib + AU-16770

EGFR mutation|Lung Adenocarcinoma|osimertinib + AU-16770

ensartinib

EGFR mutation|Non Small Cell Lung Cancer|ensartinib